Dr. Reddy's Laboratories financials

·Pharma & HealthChart ›
Latest results Q2 FY27 · Jul–Sep 2026
Revenue
₹8,698cr−1.5% on Q2 FY26
Net profit
₹913cr−31.7% on Q2 FY26
EBITDA margin
19.9%−2.9 pts on Q2 FY26
EPS
₹11.10−31.4% on Q2 FY26

Quarterly results

Every quarter ›
₹ croreQ2 FY27Q2 FY26Change
Revenue8,6988,828−1.5%
EBITDA1,7312,010−13.9%
EBITDA margin19.9%22.8%−2.9 pts
Profit before tax1,2351,739−28.9%
Net profit9131,337−31.7%
EPS₹11.10₹16.18−31.4%

Over time

Q2 FY27 · Jul–Sep 2026latest
Revenue₹8,698 crNet profit₹913 crNet margin10.5%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
1,11,506————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
4,6115,3604,7965,1165,028
3193393780.0—
6,2946,2944,1851,6521,347
1,13,508————
33,09733,70032,64428,01124,670
—+3.2%+16.5%+13.5%—
4,8616,4548,5477,9336,349
14.7%19.2%26.2%28.3%25.7%
2,7194,3956,8436,4635,099
2,7604,1585,7255,5784,507
8.3%12.3%17.5%19.9%18.3%
₹33.53₹50.25₹67.73₹66.80₹53.98
—−25.8%+1.4%+23.8%—
—5,6744,6434,5435,887
—−3,841−3,440−2,744−1,886
1,8331,8331,2031,8004,001
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

DRREDDY₹1,335.40

Dr. Reddy's Laboratories Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMACIPLALUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹1.12L Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————1,11,505.9
- Cash, Equiv & ST Investments5,027.55,115.74,796.15,360.14,611.0
+ Minority Interest—0.0377.8339.4319.1
+ Total Debt1,347.21,652.34,184.56,293.56,293.5
Enterprise Value————1,13,507.5
Revenue24,669.728,011.132,643.933,700.233,097.4
Growth %, YoY—+13.5+16.5+3.2—
EBITDA6,349.07,933.18,547.16,453.54,860.5
Margin %25.7428.3226.1819.1514.69
EBIT5,098.86,463.16,843.44,394.72,719.1
Net Income4,507.35,577.95,725.24,157.62,759.7
Margin %18.2719.9117.5412.348.34
EPS, Adj (current shares)53.9866.8067.7350.2533.53
Growth %, YoY—+23.8+1.4-25.8—
Cash from Operations5,887.34,543.34,642.85,673.7—
Capital Expenditures-1,886.4-2,743.5-3,439.8-3,840.5—
Free Cash Flow4,000.91,799.81,203.01,833.21,833.2
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Dr Reddy's financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Dr. Reddy's Laboratories (NSE: DRREDDY) had a market capitalisation of ₹1,12,308 crore at the 29 October 2026 close (₹1,345.00 a share), a PE ratio of 40.1 on the last four quarters' profit and a price-to-book ratio of 2.89. In FY26 its consolidated net profit attributable to shareholders was ₹4,196 crore on revenue of ₹33,700 crore; in Q2 FY27 (July–September 2026) it was ₹925 crore, down 31.3% year on year. Its debt-to-equity ratio was 0.15 on 30 September 2026. Promoters held 26.63% of the shares on 30 September 2026.

Dr Reddy's Q2 FY27 results
filed 23 October 2026
Share price used
₹1,345.00 · 29 October 2026 close
Latest balance sheet
30 September 2026
Shareholding pattern
30 September 2026
Share price and live chart
₹1,345.00 · 29 Oct close

Dr Reddy's at a glance · consolidated

Market cap
₹1,12,308 Crat ₹1,345.00 · 29 Oct close
PE ratio (last 4 quarters)
40.126.8 on FY26 profit
Price to book (PB)
2.89book value ₹464.75 a share
ROE (FY26)
11.8%−6.6 pts vs FY25ROCE 11.3%
Debt to equity
0.15net cash ₹1,048 Cr
Promoter holding
26.63%unchanged vs 30 Jun 202630 September 2026
Dividend yield
0.59%₹8 a share in 12 months
Net worth
₹38,807 Cr+7.8% vs 30 Sep 202530 September 2026
Free cash flow (FY26)
₹1,833 Cr+52.4% vs FY25

Questions

What is the Dr Reddy's PE ratio today?

Dr Reddy's PE ratio is 40.1 at the 29 October 2026 close (₹1,345.00 a share): a market capitalisation of ₹1,12,308 crore divided by consolidated net profit attributable to shareholders of ₹2,800 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit attributable to shareholders (₹4,196 crore) it is 26.8.

What is the Dr Reddy's PB ratio (price to book value)?

Dr Reddy's price-to-book (PB) ratio is 2.89 at the 29 October 2026 close: a market capitalisation of ₹1,12,308 crore divided by shareholders' equity (book value) of ₹38,807 crore on 30 September 2026. That is a book value of ₹464.75 per share against a share price of ₹1,345.00.

What is the Dr Reddy's net worth?

Dr Reddy's net worth — shareholders' equity in its consolidated balance sheet — was ₹38,807 crore on 30 September 2026, up 7.8% from ₹36,014 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹1,12,308 crore at the 29 October 2026 close.

What is the Dr Reddy's market cap?

Dr Reddy's market capitalisation was ₹1,12,308 crore (₹1.12 lakh crore) at the 29 October 2026 close: 83.5 crore shares at ₹1,345.00 each.

What is the Dr Reddy's EPS?

Dr Reddy's basic earnings per share (EPS) were ₹50.41 in FY26, against ₹67.89 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹33.61.

What is the Dr Reddy's dividend in 2026 and its record date?

In 2026, Dr Reddy's has declared one dividend: ₹8 with record date 10 July 2026.

Is Dr Reddy's debt free?

No. Dr Reddy's had borrowings of ₹5,826 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.15. Its cash and current investments were ₹6,874 crore, so it held net cash of ₹1,048 crore.

What is the Dr Reddy's debt to equity ratio?

Dr Reddy's debt-to-equity ratio was 0.15 on 30 September 2026: borrowings of ₹5,826 crore against total equity of ₹39,126 crore. A year earlier, on 30 September 2025, it was 0.12.

What is the Dr Reddy's dividend yield?

Dr Reddy's dividend yield is 0.59% at the 29 October 2026 close: dividends of ₹8 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹1,345.00. They were ₹8 on 10 July 2026.

What is the Dr Reddy's ROE and ROCE?

In FY26, Dr Reddy's return on equity (ROE) was 11.8% and its return on capital employed (ROCE) was 11.3%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 18.3% and ROCE 20.8%.

What is the Dr Reddy's shareholding pattern?

On 30 September 2026, Dr Reddy's shares were held by promoters 26.63%, foreign portfolio investors (FII/FPI) 31.39%, domestic institutions (DII) 31.88% (including mutual funds at 14.14%) and retail and other non-institutional investors 9.90%. Over the year, FII holding was down 4.13 percentage points from 35.52% and DII holding was up 3.90 percentage points from 27.98%.

What are the Dr Reddy's latest quarterly results?

Dr Reddy's latest results are for Q2 FY27 (July–September 2026), filed on 23 October 2026: consolidated net profit attributable to shareholders ₹925 crore, down 31.3% from ₹1,347 crore in Q2 FY26; revenue from operations ₹8,698 crore, down 1.5% year on year.

What is the Dr Reddy's book value per share?

Dr Reddy's book value per share was ₹464.75 on 30 September 2026: shareholders' equity of ₹38,807 crore divided by the 83.5 crore shares in issue, up 7.8% from ₹431.31 a year earlier. The share price at the 29 October 2026 close was ₹1,345.00.

What is the Dr Reddy's promoter holding?

Promoters held 26.63% of Dr Reddy's on 30 September 2026, down 0.01 percentage points from 26.64% the previous quarter and down 0.01 percentage points from 26.64% a year earlier, according to the shareholding pattern filed with NSE.

What is the Dr Reddy's free cash flow?

In FY26, Dr Reddy's generated ₹5,674 crore of cash from operations and spent ₹3,841 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹1,833 crore. In FY25 it was ₹1,203 crore.

What is the Dr Reddy's revenue and profit in FY26?

In FY26 (April 2025–March 2026), Dr Reddy's consolidated net profit attributable to shareholders was ₹4,196 crore, down 25.8% from ₹5,655 crore in FY25, on revenue from operations of ₹33,700 crore (up 3.2%). Over three years, from FY23, net profit was down 6.9%.

When are the Dr Reddy's next results?

Dr Reddy's has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.

How does the Dr Reddy's PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Dr Reddy's PE ratio is 26.8, the third highest of the four: Sun Pharma 36.8, Cipla 28.3 and Lupin 17.1, a peer average of 27.4. Each is the company's market capitalisation at that price divided by its FY26 net profit.

How does Dr Reddy's compare with its peers?

On FY26 consolidated figures, against Sun Pharma, Cipla and Lupin: Dr Reddy's operating margin of 13.0% is the lowest of the four (Sun Pharma 25.3%, Cipla 16.6%, Lupin 26.6%; peer average 22.8%); its return on equity of 11.8% is the lowest of the four (Sun Pharma 14.7%, Cipla 11.8%, Lupin 26.9%; peer average 17.8%); its revenue growth over three years of 11.0% a year is the second highest of the four (Sun Pharma 10.0% a year, Cipla 7.4% a year, Lupin 18.9% a year; peer average 12.1% a year).

Dr Reddy's vs Sun Pharma: how do they compare?

In FY26, Dr Reddy's earned net profit attributable to shareholders of ₹4,196 crore on revenue of ₹33,700 crore, against ₹11,479 crore on ₹58,462 crore for Sun Pharma. Dr Reddy's operating margin was 13.0% (Sun Pharma 25.3%) and its return on equity 11.8% (Sun Pharma 14.7%). At the 29 October 2026 close, Dr Reddy's market capitalisation was ₹1,12,308 crore against ₹4,22,517 crore for Sun Pharma, and its PE ratio on FY26 profit 26.8 against 36.8.

Where do these Dr Reddy's figures come from?

From Dr. Reddy's Laboratories' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.